Semaglutide vs. Tirzepatide: The Complete 2026 Comparison
Tirzepatide produces about 50% more weight loss than semaglutide. But there are trade-offs — here\'s the full head-to-head.
Get Either One — From $179/mo →The Bottom Line
- For maximum weight loss: tirzepatide (~21% vs. semaglutide ~15%)
- For longest track record + cardiovascular evidence: semaglutide (Wegovy SELECT trial)
- For oral option: semaglutide (Rybelsus) — tirzepatide has no oral form
- For cost (compounded): semaglutide is cheaper ($179 vs. $249/mo)
- For insurance coverage: semaglutide is more widely covered (longer on market)
Side-by-Side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names | Wegovy, Ozempic, Rybelsus | Zepbound, Mounjaro |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Avg weight loss | ~15% (Wegovy STEP-1) | ~21% (Zepbound SURMOUNT-1) |
| Top-band loss | 32% lost ≥20% | 57% lost ≥20% |
| A1c reduction | ~1.5-1.8% | ~1.9-2.6% |
| Cardiovascular evidence | SELECT: 20% MACE reduction | SUMMIT: HFpEF benefit |
| Forms available | Injection (weekly), pill (daily) | Injection (weekly) only |
| FDA approval (weight) | 2021 (Wegovy) | 2023 (Zepbound) |
| Cost (branded list) | Wegovy $1,349/mo | Zepbound $1,069/mo (or $349 LillyDirect) |
| Cost (compounded) | $179-249/mo | $249-399/mo |
| Side effects | Nausea 44%, GI similar | Nausea 29-39%, possibly less than sema |
| Insurance coverage | Broader | Improving rapidly |
Weight Loss Trial Data
STEP-1 (Wegovy 2.4 mg, n=1,961, 68 weeks):
- Average loss: 14.9%
- ≥5% loss: 86%
- ≥10% loss: 69%
- ≥15% loss: 50%
- ≥20% loss: 32%
SURMOUNT-1 (Zepbound 15 mg, n=2,539, 72 weeks):
- Average loss: 20.9%
- ≥5% loss: 91%
- ≥10% loss: 84%
- ≥15% loss: 73%
- ≥20% loss: 57%
- ≥25% loss: 36%
When to Choose Semaglutide
- Insurance covers Wegovy/Ozempic but not Zepbound/Mounjaro
- You have established cardiovascular disease (SELECT trial evidence)
- You prefer an oral option (Rybelsus)
- Cost is the priority (compounded sema cheaper)
- You want the most-studied long-term safety data
When to Choose Tirzepatide
- You want maximum weight loss
- You\'ve tried semaglutide and plateaued before goal
- You have heart failure with preserved ejection fraction (HFpEF)
- You have obstructive sleep apnea + obesity (Zepbound 2024 indication)
- Insurance covers Zepbound/Mounjaro
Frequently Asked Questions
Is tirzepatide better than semaglutide?
For weight loss, yes — tirzepatide produces about 50% more weight loss in trials (~21% vs. ~15%). Tirzepatide also achieves better A1c reduction in diabetes. Semaglutide has longer real-world track record and broader insurance coverage. Cost-equivalent compounded versions narrow the cost gap.
GLP-1 vs. GIP — what's the difference?
GLP-1 and GIP are both incretin hormones. GLP-1 receptor agonists (semaglutide) target only GLP-1. Tirzepatide targets both GLP-1 AND GIP — the dual mechanism produces stronger results.
Should I start with semaglutide or tirzepatide?
Both are reasonable. Semaglutide is the more established option with 15+ years of data and broader insurance coverage. Tirzepatide produces stronger results but is newer. Many patients start with semaglutide and switch to tirzepatide if they want more weight loss.
Can I switch from semaglutide to tirzepatide?
Yes. Most clinicians wait 1 week after the last semaglutide dose, then start tirzepatide at the 2.5 mg starter dose (or 5 mg if previously on full semaglutide). The dual mechanism may produce different side effect intensity.